Abstract
Competition within the medical aesthetic marketplace is increasing and it is tempting for practitioners to look for low-price products to maximise their profit. However, there are several risks associated with prioritising quantity over quality, one of which is the marketing of counterfeit cosmetic injectables. Shailesh Patel explains why falsified products are problematic and outlines European legislation in this area
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
